Integrated Clinical, Tissue, and Biomarker Data Base Core (ICTBD Core)

摘要(共享资源-ICTBD核心) 综合临床和组织生物库/生物标志物数据库(ICTBD)核心的总体目标是 加强和升级我们现有的ICTBD核心，它与我们的临床资源核心整合在一起。这将是 通过多维翻译研究方法来实现，该方法利用 合作伙伴关系的研究/推广中心、临床网络、社区合作伙伴和学术合作伙伴 通过第一个U54筹资周期(2009-2015年)制定。合作伙伴使用翻译研究 根据两个翻译模块(T1-基础/生物医学研究和T2-临床/实施 研究)。在第二个U54周期(2015-2020年)期间，伙伴关系提议利用ICTBD核心来 加强现有的T1活动，并促进将第一个U54周期中开发的项目从T1转移到T2。 我们将通过以下方式实现这一目标：1)继续建立网络，以加强生物样品/数据 收集和促进转译研究，2)提供患者同意/参与生物显微镜和 临床研究方案，3)促进双向交流、教育/培训的平台，以及 伙伴关系T1/T2活动与社区癌症外展之间的信息传播 核心，4)为T1到T2过渡提供管理支持，如IRB准备、监控和患者 招募以加强未被充分代表的患者参与临床试验，以及5)与 我们的社区合作伙伴和社区肿瘤学家将继续建立和维持全面的 聚焦于非裔美国人和拉丁裔乳腺癌、结肠癌和前列腺癌的Biospecimen信息库 为了确定用于评估癌症发病和进展风险的新标记物 可能是种族群体独有的，并减少癌症健康差异。这些活动将对双方都产生双重的影响 通过以下方式加强基民盟/加州大学洛杉矶分校的翻译研究机构能力 加州大学洛杉矶分校-JCCC的资源，并使UCLA-JCCC的机会多样化，以提高代表不足的参与度 研究的参与者。

ABSTRACT (Shared Resources-ICTBD Core) The overall objective of the Integrated Clinical and Tissue Biorepository/Biomarker Data Base (ICTBD) Core is to enhance and upgrade our current ICTBD Core which is integrated with our Clinical Resource Core. This will be accomplished through a multi-dimensional translational research approach which leverages the Partnership's research/outreach Cores, clinical networks, community partners, and academic partners developed through the 1st U54 funding cycle (2009-2015). The Partnership uses Translational Research according to the two translational blocks (T1- Basic/Biomedical Research and T2- Clinical/Implementation Research). During the 2nd U54 Cycle (2015-2020), the Partnership proposes to utilize the ICTBD Core to both enhance existing T1 activities, and facilitate the transfer of projects developed in 1st U54 cycle from T1 to T2. We will accomplish this through the following: 1) continue building networks to enhance biospecimen/data collection and facilitate translational research, 2) provide patient consent/engagement into biospecimen and clinical research protocols, 3) facilitate a platform of bi-directional exchange, education/training, and information dissemination between the Partnership's T1/T2 activities and the Community Cancer Outreach Core, 4) provide administrative support for T1 to T2 transition such as IRB preparation, monitoring, and patient recruitment to enhance underrepresented patient participation in clinical trials, and 5) work in partnership with our community partners and community oncologists to continue to build and sustain a comprehensive biospecimen repository with focus on breast, colon, and prostate cancers from African Americans and Latinos for the purpose of identification of novel markers for assessing risk of cancer incidence and progression that may be unique to ethnic groups and reduce cancer health disparities. These activities will dually enrich both sides of the CDU/UCLA Partnership by bolstering CDU's institutional capacity for translational research with UCLA-JCCC resources, and diversifying access for UCLA-JCCC to improve engagement of underrepresented participants in research.